Vivos Therapeutics, Inc. - 10-Q Filing
Vivos Therapeutics reports Q3 financial results including details on March 2026 PIPE offering and Series B non-convertible preferred stock issuance.
Tickers: $VVOS
Vivos Therapeutics reports Q3 financial results including details on March 2026 PIPE offering and Series B non-convertible preferred stock issuance.
Tickers: $VVOS